2022, Number 3
<< Back Next >>
Med Int Mex 2022; 38 (3)
New perspectives for the ambulatory or early treatment of COVID-19 based on chloroquine-hydroxychloroquine
Cavenecia PR, Mamani LQ, Fernández-Silva FS
Language: Spanish
References: 12
Page: 736-738
PDF size: 171.27 Kb.
Text Extraction
No abstract.
REFERENCES
Zúñiga B, Álvarez L, Enríquez M, Fyda J. Nuevas perspectivaspara el tratamiento ambulatorio o en etapas tempranas deCOVID-19. Med Int Méx 2020; 36 (3): 323-331. https://doi.org/10.24245/mim.v36id.4138.
Jang CH, Choi JH, Byun MS, Jue DM. Chloroquine inhibitsproduction of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophagesby different modes. Rheumatology (Oxford) 2006; 45 (6):703-710. doi:10.1093/rheumatology/kei282,
Randolph VB, Winkler G, Stollar V. Acidotropic aminesinhibit proteolytic processing of flavivirus prM protein.Virology 1990; 174 (2): 450-458. doi:10.1016/0042-6822(90)90099-d.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, X, et al. Clinicalcourse and risk factors for mortality of adult inpatientswith COVID-19 in Wuhan, China: a retrospective cohortstudy. Lancet 2020; 395 (10229): 1054-1062. doi: 10.1016/S0140-6736(20)30566-3.
Sahraei Z, Shabani M, Shokouhi S, Saffaei A. Aminoquinolinesagainst coronavirus disease 2019 (COVID-19): chloroquineor hydroxychloroquine. Int J Antimicrob Agents 2020;55 (4): 105945. doi:10.1016/j.ijantimicag.2020.105945.
Yao X, Ye F, Zhang M, Cui C, et al. In vitro antiviral activityand projection of optimized dosing design of hydroxychloroquinefor the treatment of severe acute respiratorysyndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020;
71 (15): 732-739. doi:10.1093/cid/ciaa237.7. Oliver ME, Hinks TS, Azithromycin in viral infections. RevMed Virol 2021; 31: e2163. DOI: 10.1002/rmv.2163.
Poschet J, Perkett E, Timmins G, Deretic V. Azithromycin andciprofloxacin have a chloroquine-like effect on respiratoryepithelial cells. Bio Rxiv 2020; 008631. doi: https://doi.org/10.1101/2020.03.29.008631.
Gautret .P, Lagier. JC, Parola. P, et al. Hydroxychloroquineand azithromycin as a treatment of COVID-19: results ofan open-label non-randomized clinical trial. Int J AntimicrobAgents 2020; 56 (1): 105949. doi:10.1016/j.ijantimicag.2020.105949.
Chorin E, Dai M, Shulman E, Wadhwani L, Bar-Cohen R, BarbhaiyaC, et al. The QT interval in patients with SARS-CoV-2infection treated with hydroxychloroquine/azithromycin.medRxiv 2020.04.02.20047050. https://doi.org/10.1101/2020.04.02.20047050.
Aktar S, Talukder A, Ahamad MM, Kamal AHM, Khan JR,Protikuzzaman M, et al. Machine learning approaches toidentify patient comorbidities and symptoms that increasedrisk of mortality in COVID-19. Diagnostics (Basel) 2021;11 (8): 1383. doi:10.3390/diagnostics11081383.
Ibáñez S, Martínez O, Valenzuela F, Silva F, Valenzuela O.Hidroxicloroquina y cloroquina en COVID-19: ¿deberíanusarse como terapia estándar? Clin Rheumatol 2020; 39(8): 2461-2465. doi: 10.1007 / s10067-020-05202-4.
Full text